NASDAQ · Biotechnology

Prelude Therapeutics Incorporated (PRLD) Stock

$3.89 +0.26% NASDAQ: PRLD Healthcare

Valuation

MetricValue
Price$3.89
Market Cap$221.47M
P/E Ratio-4.65
P/B Ratio2.70
P/S Ratio9.32
EPS (TTM)$-1.29
52-Week High$6.83
52-Week Low$1.15
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-75.35%
ROA-31.94%
ROCE-44.54%
Gross Margin-875.00%
Operating Margin-875.00%
Net Margin-269.75%
Debt/Equity0.13
Current Ratio2.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$7.0M$12.0M
Operating Profit$-114.0M$-124.0M$-132.0M$-140.0M$-105.0M
Net Profit$-112.0M$-115.0M$-122.0M$-127.0M$-99.0M
EPS$-2.33$-2.27$-2.02$-1.68$-1.29
Op Margin———-1995.9%-861.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$305.0M$221.0M$278.0M$176.0M$141.0M
Total Liabilities$19.0M$25.0M$41.0M$44.0M$73.0M
Cash$32.0M$31.0M$25.0M$12.0M$35.0M
Borrowings$2.0M$2.0M$17.0M$18.0M$18.0M

Latest News

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why Zacks · Jul 17, 2026 Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD) Insider Monkey · May 31, 2026 Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts Simply Wall St. · May 16, 2026 Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire · May 12, 2026 Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet Zacks · May 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-84.0M$-84.0M$-107.0M$-103.0M$-56.0M
Investing Cash Flow$-266.0M$79.0M$-38.0M$89.0M$53.0M
Financing Cash Flow$3.0M$0$0$0$0
Net Cash Flow$-182.0M$-1.0M$-5.0M$-13.0M$22.0M
Free Cash Flow$-86.0M$-87.0M$-111.0M$-104.0M$-56.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.06
EV / EBITDA-3.40
FCF Yield-15.92%
Quick Ratio4.07
Interest Coverage0.00
Return 1Y331.87%
Return 3Y-14.19%
Return 5Y-84.33%

Ownership

Insiders Held13.80%
Institutions Held64.81%
Institutions Float Held75.18%
Institutional HolderSharesReport Date
Orbimed Advisors LLC.16,589,4422026-03-31
Baker Bros. Advisors, LP10,123,8242026-03-31
Kynam Capital Management, LP1,592,5512026-03-31
Vanguard Capital Management LLC1,230,4062026-03-31
EcoR1 Capital, LLC947,0492026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated is led by CEO Krishna Vaddi, employs 131 people, headquartered in US, publicly traded since 2020.

Prelude Therapeutics Incorporated (PRLD) stock trades at $3.89 with a market capitalization of $221.47M. The stock is valued at a price-to-earnings (P/E) ratio of -4.65, price-to-book of 2.70, price-to-sales of 9.32. Over the past 52 weeks the stock has ranged between $1.15 and $6.83, and currently trades 43.0% below its 52-week high.

On profitability, Prelude Therapeutics Incorporated generates a return on equity (ROE) of -75.35%, return on capital employed of -44.54%, an operating margin of -875.00%, a net profit margin of -269.75%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides